Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELUDE: Secukinumab for Lichen Planus
2019-003588-24Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lichen planus (LP) comparing Secukinumab 300 mg with Placebo (2 arms). Primary endpoint: Investigator's Global Assessment (IGA) response at week 16. Started Feb 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on 2019-003588-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003588-24.